VHL and nonpapillary renal cell carcinoma: However, some VHL-mutant ccRCCs were less responsive to HIF2α depletion or HIF2α inhibitor treatment (Choueiri and Kaelin, 2020), suggesting that VHL has other cellular targets that are involved in ccRCC development.